Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-866 perioperative pembrolizumab in muscle-invasive bladder cancer
2018-003808-39Phase 3Active
- Sponsor
- Merck & Co.
- Start
- Mar 2019
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in muscle-invasive bladder carcinoma (MIBC) comparing Perioperative pembrolizumab arm with Perioperative placebo arm (2 arms). Primary endpoint: Event-Free Survival. Started Mar 2019; status: active.
02
Drugs
03
Conditions
muscle-invasive bladder carcinoma (MIBC)
Beyond the preview
Go deeper on 2018-003808-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003808-39.